# Ollin Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ollin-biosciences

- Industry: Biotechnology
- Headquarters: Austin, US
- Website: www.ollin.bio
- Total disclosed funding: $207M
- Latest round: Series B (May 14, 2026)
- Investors on record: 10

## About

Based in the US, Ollin Biosciences, Inc. specializes in developing therapies for severe ophthalmic diseases, focusing on innovative solutions to improve patient outcomes in vision preservation.Ollin Biosciences, Inc. was founded in 2023 and is headquartered in Austin, US. The company is dedicated to creating therapies for ophthalmic conditions. In June 2026, Ollin Biosciences, Inc. raised USD 330 million in series B funding co-led by TCG Crossover Management and ARCH Venture Partners, with participation from Monograph Capital, Mubadala Capital, Andreessen Horowitz, Blackstone Multi-Asset Advisors, Commodore Capital, CPP Investment Board, RA Capital Management, and T Rowe Price. The company will use the funding to support late-stage clinical trials for treatments targeting diabetic macular edema and wet age-related macular degeneration, and to advance a therapy for thyroid eye disease and Graves’ disease into clinical development.

The founder's prior experience includes involvement in similar ventures, although specific details are not available.Ollin Biosciences is focused on developing advanced therapies for serious ophthalmic diseases, primarily targeting conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and thyroid eye disease (TED). The company's core product offerings include OLN324, a higher potency, small format VEGF/Ang2 bispecific antibody designed for wet AMD and DME treatment, and OLN102, a first-in-class IGF-1R/TSHR bispecific antibody aimed at TED. These therapies work by targeting specific biological pathways associated with these conditions, aiming to improve vision preservation and enhance the quality of life for patients. Ollin’s products are aimed primarily at healthcare providers, hospitals, and clinics in the United States and select international markets, addressing critical needs in the management of debilitating eye diseases.Ollin Biosciences generates revenue through the development and commercialization of its therapeutic products, which are positioned for direct sales to healthcare providers and institutions involved in the treatment of ophthalmic conditions. The company’s transaction structure primarily operates on a B2B basis, with potential partnerships and collaborations being established with healthcare entities and pharmaceutical distributors. These relationships facilitate the distribution of Ollin's flagship products, specifically OLN324 and OLN102, to a diverse client base that includes hospitals, specialty clinics, and healthcare networks. As the products advance through clinical trials and regulatory approval phases, the company aims to establish pricing strategies that align with the value delivered through its innovative therapies, ensuring access to effective treatment options for patients suffering from vision-threatening diseases. Ollin Biosciences plans to leverage the recently raised USD 100 mn in funding to enhance its clinical and preclinical programs and assemble a robust ophthalmology treatment pipeline. The company is targeting the launch of new products designed for ophthalmic diseases, with a focus on expanding into international markets by 2026. This strategic utilization of funds aims to support the development of their innovative therapies and meet the growing demand in the ophthalmic treatment landscape.

## Funding rounds

- Series B, May 14, 2026, $156M — ARCH Venture Partners, T Rowe Price, CPP Investment Board, Andreessen Horowitz, RA Capital Management, Blackstone Multi-Asset Advisors, Mubadala Capital, Commodore Capital, TCG Crossover Management, Monograph Capital
- Series A, Sep 17, 2025, $51M — ARCH Venture Partners, Mubadala Capital, Monograph Capital

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series A, Series B
- Monograph Capital (https://capitalatlas.ai/funds/monograph-capital) — Series A, Series B
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series B
- CPP Investment Board — Series B
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B
- Blackstone Multi-Asset Advisors (https://capitalatlas.ai/funds/blackstone-multi-asset-advisors) — Series B
- Commodore Capital (https://capitalatlas.ai/funds/commodore-capital) — Series B
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series B